The tablet doesn't use backlighting, and has other features meant to minimize eye strain.

This review uniquely bridges the relationship between 0D, 1D, and 2D structural motifs of halide perovskites and their distinct optoelectronic properties; such as photoluminescence, charge transport, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. ORLANDO — In this video from the American Academy of ...

Philip J. Ferrone, MD, provided an overview of the TEASE 2 study (NCT02402660), a phase 2 clinical trial evaluating gildeuretinol in patients with moderate severity Stargardt disease, at the American ...

In the Phase 2 TEASE 2 trial, gildeuretinol was well tolerated and showed promising trends in slowing ellipsoid zone loss and preserving low-luminance visual acuity in patients with Stargardt disease.

Investigators evaluated the effects of a complement C1q inhibitor on retinal structure and function in the setting of geographic atrophy. A geographic atrophy drug in phase 2 clinical trial shows ...

A gene therapy that targets a form of retinitis pigmentosa showed a signal to improve retinal function for up to 3 years after treatment, according to a small clinical trial. The phase 2 SKYLINE trial ...

Laru-zova showed sustained improvements in visual function and was well-tolerated in both SKYLINE and DAWN trials, addressing the unmet need in XLRP treatment. DAWN trial data indicated early and ...

Recent research highlights inferred sensitivity mapping as a promising method to assess retinal function in geographic atrophy, enhancing clinical trial outcomes. Currently, the treatments available ...

Syncona Ltd, a leading life science investor, today notes that its portfolio company Beacon Therapeutics ("Beacon") announced new results from two Phase 2 trials, SKYLINE and DAWN, evaluating the ...